December 06, 2016
Office of Public Affairs
655 West Baltimore Street
Bressler Research Building 14-002
Baltimore, Maryland 21201-1559
Contact Media Relations
Friday, February 05, 2021
UM School of Medicine Researchers Demonstrate Strong Immune Response for New COVID-19 Vaccine in Pre-Clinical Tests
Researchers at the University of Maryland School of Medicine (UMSOM) have found promising results in pre-clinical studies for a new experimental vaccine against COVID-19 made by Novavax. The vaccine was found to generate a robust immune response in animals exposed to the vaccine with strong data indicating safety and efficacy, according to the study published recently in the journal Nature Communications. The results have been used to begin testing the vaccine in human trials in the U.S. with a Phase 3 trial that recently launched at the UMSOM’s Center for Vaccine Development and Global Health.
Tuesday, June 16, 2020
UM School of Medicine Researchers Receive Federal Funding to Rapidly Test New Treatments for COVID-19
Researchers at the University of Maryland School of Medicine (UMSOM) will be partnering on an agreement funded by the federal government’s Defense Advanced Research Projects Agency (DARPA) to rapidly test hundreds of drugs, approved and marketed for other conditions, to see whether any can be repurposed to prevent or treat COVID-19. The compounds will be tested in studies using state-of-the-art technologies in the laboratory of coronavirus researcher Matthew Frieman, PhD., Associate Professor of Microbiology and Immunology at the University of Maryland School of Medicine. UMSOM will receive up to $3.6 million over the next year to fund this effort.
Monday, June 15, 2020
UM School of Medicine Researchers Help Identify Potent Antibody Cocktail with Potential to Treat COVID-19
Researchers at the University of Maryland School of Medicine (UMSOM) evaluated several human antibodies to determine the most potent combination to be mixed in a cocktail and used as a promising anti-viral therapy against the virus that causes COVID-19. Their research, conducted in collaboration with scientists at Regeneron Pharmaceuticals, was published today in the journal Science. The study demonstrates the rapid process of isolating, testing and mass-producing antibody therapies against any infectious disease by using both genetically engineered mice and plasma from recovered COVID-19 patients.
Friday, October 18, 2019
Diabetes Worsens Respiratory Illness Due to Abnormal Immune Response, UM School of Medicine Study Finds
Since the Middle East respiratory syndrome coronavirus (MERS-CoV) first emerged in Saudi Arabia in 2012, there have been more than 2,400 confirmed cases of the infection, resulting in greater than 800 deaths – an alarming fatality rate of 35 percent. For this reason, researchers have been eager to identify any risk factors that contribute to the development of severe or lethal disease. Current clinical evidence points to diabetes as a major risk factor in addition to other comorbidities including kidney disease, heart disease, and lung disease.
Wednesday, February 17, 2016
In a new study, University of Maryland School of Medicine researchers have had promising results with a new treatment for Middle East Respiratory Syndrome (MERS). The study, published today in the journal Science Translational Medicine, found a new treatment that protected mice from MERS infection.
Monday, June 29, 2015
First-Ever Possible Treatments for Middle East Respiratory Syndrome; UMSOM Researchers Identify Two Promising Candidates to Prevent and Treat Deadly Epidemic
University of Maryland School of Medicine scientists and Regeneron Pharmaceuticals, Inc., have discovered and validated two therapeutics that show early promise in preventing and treating MERS, which can cause severe respiratory symptoms, and has a death rate of 40 percent.